Top Markets
Coin of the day
Newron Pharmaceuticals S.p.A. Newron Pharmaceuticals S.p.A.

Newron Pharmaceuticals S.p.A.

NP5
Rank in Stocks #15970
Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in... Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in Bresso, Milano, with a dedicated team of 24 full-time employees. The company's core mission is the discovery and advancement of innovative pharmaceutical products, particularly focusing on new therapies for Central Nervous System (CNS) disorders and pain management. Among its leading candidates, safinamide is currently undergoing Phase III clinical trials for the treatment of Parkinson's disease. Additionally, ralfinamide is being developed as a potential therapy for neuropathic pain. The firm's pipeline further includes a range of projects at various preclinical and clinical development stages, such as HF0220 for neuroprotection, NW-3509 for schizophrenia, and pruvanserin and sarizotan for other CNS conditions.
Share Price
$15.42
Market Cap
$320.83M
Change (1 day)
-1.52%
Change (1 year)
40.67%
Country
IT
Trade Newron Pharmaceuticals S.p.A. (NP5)

Category

P/B ratio for Newron Pharmaceuticals S.p.A. (NP5)
P/B ratio as of 2026 TTM: 0
According to Newron Pharmaceuticals S.p.A. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Newron Pharmaceuticals S.p.A. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.828 -
US
7.5116 -
NL
8.2199 -
US
3.9942 -
AU
- -
CH